Loading
Acerand Therapeutics develops small-molecule cancer medicines. Its programmes include ACE-232, a tablet that blocks the CYP11A1 enzyme at the start of steroid hormone production, in an early trial for prostate cancer that no longer responds to hormone therapy, and a selective PARP1 inhibitor.
Acerand Therapeutics lists addresses in Shanghai and Carmel, Indiana, and says it concentrates its drug discovery on oncology small molecules; its site says it was founded by industry veterans with LAV. ACE-232 is a CYP11A1 inhibitor: the FDA cleared it for clinical investigation in January 2025, the first-in-human phase 1 trial NCT06801236 in metastatic castration-resistant prostate cancer (given with dexamethasone and fludrocortisone, at US and Chinese sites) began in 2025, and China's CDE cleared a study in July 2025. The company also reported first patient enrolment in a phase 1/2 trial of a selective PARP1 inhibitor in March 2024 and preliminary clinical data in May 2025, and an update on ACE-106 in April 2026. Its first cancer trial registered under the sponsor name Acerand Therapeutics (Hong Kong) Limited, NCT06801236, was posted on ClinicalTrials.gov in January 2025.
Shares PARP inhibitors, PARP, Metastatic castration-resistant prostate cancer.
Shares PARP inhibitors, Metastatic castration-resistant prostate cancer.
Shares PARP inhibitors, Metastatic castration-resistant prostate cancer.
Shares PARP inhibitors, PARP.
Shares PARP inhibitors, PARP.
Shares PARP inhibitors, PARP.
Shares PARP inhibitors, PARP.
Shares PARP inhibitors, PARP.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/